- Latest available (Revised)
- Point in Time (16/04/2014)
- Original (As adopted by EU)
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Point in time view as at 16/04/2014.
There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council, Division D..
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
the title of the clinical trial;
the EU trial number;
the sponsor's protocol code number specific for all versions of it (if relevant);
the date and number of the version, to be updated when it is amended;
a short title or name assigned to the protocol; and
the name and address of the sponsor, as well as the name and function of the representative or representatives of the sponsor authorised to sign the protocol or any substantial modification to the protocol.
a statement that the clinical trial is to be conducted in compliance with the protocol, with this Regulation and with the principles of good clinical practice;
a comprehensive list of all investigational medicinal products and of all auxiliary medicinal products;
a summary of findings from non-clinical studies that potentially have clinical significance and from other clinical trials that are relevant to the clinical trial;
a summary of the known and potential risks and benefits including an evaluation of the anticipated benefits and risks to allow assessment in accordance with Article 6; for subjects in a clinical trial in an emergency situation, the scientific grounds for expecting that the participation of the subjects has the potential to produce a direct clinically relevant benefit shall be documented;
where patients were involved in the design of the clinical trial, a description of their involvement;
a description of, and justification for, the dosage, the dosage regime, the route and mode of administration, and the treatment period for all investigational medicinal products and auxiliary medicinal products;
a statement of whether the investigational medicinal products and auxiliary medicinal products used in the clinical trial are authorised; if authorised, whether they are to be used in the clinical trial in accordance with the terms of their marketing authorisations, and, if not authorised, a justification for the use of non-authorised auxiliary medicinal products in the clinical trial;
a description of the groups and subgroups of the subjects participating in the clinical trial, including, where relevant, groups of subjects with specific needs, for example. age, gender, participation of healthy volunteers, subjects with rare and ultra rare diseases;
references to literature and data that are relevant to the clinical trial, and that provide background for the clinical trial;
a discussion of the relevance of the clinical trial in order to allow assessment in accordance with Article 6;
a description of the type of clinical trial to be conducted and a discussion of the trial design (including a schematic diagram of trial design, procedures and stages, if relevant);
a specification of the primary end-points and the secondary end-points, if any, to be measured during the clinical trial;
a description of the measures taken to minimise bias, including, if applicable, randomisation and blinding;
a description of the expected duration of subject participation and a description of the sequence and duration of all clinical trial periods, including follow-up, if relevant;
a clear and unambiguous definition of the end of the clinical trial in question and, if it is not the date of the last visit of the last subject, a specification of the estimated end date and a justification thereof;
a description of the criteria for discontinuing parts of the clinical trial or the entire clinical trial;
arrangements for the maintenance of clinical trial treatment randomisation codes and procedures for breaking codes, if relevant;
a description of procedures for the identification of data to be recorded directly on the Case Report Forms considered as source data;
a description of the arrangements to comply with the applicable rules for the collection, storage and future use of biological samples from clinical trial subjects, where applicable, unless contained in a separate document;
a description of the arrangements for tracing, storing, destroying and returning the investigational medicinal product and unauthorised auxiliary medicinal product in accordance with Article 51;
a description of the statistical methods to be employed, including, if relevant:
timing of any planned interim analysis and the number of subjects planned to be enrolled;
reasons for choice of sample size;
calculations of the power of the clinical trial and clinical relevance;
the level of significance to be used;
criteria for the termination of the clinical trial;
procedures for accounting for missing, unused, and spurious data and for reporting any deviation from the original statistical plan; and
the selection of subjects to be included in the analyses;
a description of the subject inclusion and exclusion criteria, including criteria for withdrawing individual subjects from treatment or from the clinical trial;
a description of procedures relating to the withdrawal of subjects from treatment or from the clinical trial including procedures for the collection of data regarding withdrawn subjects, procedures for replacement of subjects and the follow-up of subjects that have withdrawn from treatment or from the clinical trial;
a justification for including subjects who are incapable of giving informed consent or other special populations, such as minors;
a justification for the gender and age allocation of subjects and, if a specific gender or age group is excluded from or underrepresented in the clinical trials, an explanation of the reasons and justification for these exclusion criteria;
a detailed description of the recruitment and informed consent procedure, especially when subjects are incapable of giving informed consent;
a description of the treatments, including medicinal products, which are permitted or not permitted, before or during the clinical trial;
a description of the accountability procedures for the supply and administration of medicinal products to subjects including the maintenance of blinding, if applicable;
a description of procedures for monitoring subject compliance, if applicable;
a description of arrangements for monitoring the conduct of the clinical trial;
a description of the arrangements for taking care of the subjects after their participation in the clinical trial has ended, where such additional care is necessary because of the subjects' participation in the clinical trial and where it differs from that normally expected for the medical condition in question;
a specification of the efficacy and safety parameters as well as the methods and timing for assessing, recording, and analysing these parameters;
a description of ethical considerations relating to the clinical trial if those have not been described elsewhere;
a statement from the sponsor (either in the protocol or in a separate document) confirming that the investigators and institutions involved in the clinical trial are to permit clinical trial-related monitoring, audits and regulatory inspections, including provision of direct access to source data and documents;
a description of the publication policy;
duly substantiated reasons for the submission of the summary of the results of the clinical trials after more than one year;
a description of the arrangements to comply with the applicable rules on the protection of personal data; in particular organisational and technical arrangements that will be implemented to avoid unauthorised access, disclosure, dissemination, alteration or loss of information and personal data processed;
a description of measures that will be implemented to ensure confidentiality of records and personal data of subjects;
a description of measures that will be implemented in case of data security breach in order to mitigate the possible adverse effects.
adverse events or laboratory anomalies that are critical to safety evaluations and must be reported by the investigator to the sponsor, and
serious adverse events which do not require immediate reporting by the investigator to the sponsor.
eliciting and recording adverse events by the investigator, and the reporting of relevant adverse events by the investigator to the sponsor;
reporting by the investigator to the sponsor of those serious adverse events which have been identified in the protocol as not requiring immediate reporting;
reporting of suspected unexpected serious adverse reactions by the sponsor to the Eudravigilance database; and
follow-up of subjects after adverse reactions including the type and duration of follow-up.
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: